Does BPC 157 Cause Cancer?

Your body is already running a blood vessel construction program, and BPC-157 plugs directly into it.

That program exists because your tissues constantly need repair. When you damage a muscle, cut your skin, or restrict blood flow to a limb, your body releases chemical signals that tell nearby cells to grow new blood vessels toward the injury. One of the most important signals in that system is something called VEGF, which stands for vascular endothelial growth factor, and it works essentially like a distress flare that your damaged tissue fires off to pull blood vessels in its direction.

The cells that respond to that signal do so through something called VEGFR2, which is the receptor protein that sits on the surface of blood vessel cells and catches the VEGF signal when it arrives. More receptors means more sensitivity. It is the difference between a radio antenna picking up a faint signal and a full broadcast tower receiving it at full strength.

What BPC-157 appears to do is increase the number of those VEGFR2 receptors, and increase how active they are, which makes the whole system more responsive. A 2017 study using a rat hind limb ischemia model, where blood flow to the leg is surgically restricted to simulate vascular injury, found that BPC-157 upregulated VEGFR2 expression and activated the downstream signaling chain, specifically something called the VEGFR2-Akt-eNOS pathway, which ultimately increased vessel density in the damaged tissue. That is the mechanism behind the healing effect people associate with this peptide.

Now here is where the concern enters.

Tumors use the exact same pathway.

When a tumor reaches roughly one to two millimeters in diameter, it runs out of the ability to absorb nutrients and oxygen just by diffusion from surrounding tissue. At that point it needs its own blood supply to keep growing, so it starts releasing VEGF to recruit blood vessels toward itself. This process is called angiogenesis, and it is not unique to tumors, but tumors depend on it to survive past a certain size. This is actually why some of the most widely used cancer drugs work by blocking VEGF signaling. Drugs like bevacizumab essentially cut off the blood supply and starve the tumor out.

So the logical concern is straightforward. If BPC-157 is amplifying the VEGF system, and tumors depend on the VEGF system, could BPC-157 accelerate tumor growth or help an undetected tumor build its blood supply faster?

That question has not been answered in living organisms.

There is one piece of relevant data, and it points in the opposite direction of what you might expect. A 2004 conference abstract tested BPC-157 directly on SK-Mel-1 human melanoma cells in a lab dish. At concentrations of 2 nanograms and 10 nanograms, BPC-157 reduced the S-phase fraction, which is the proportion of cells actively dividing, by up to 55 percent compared to controls. The proposed mechanism was inhibition through the MAPK kinase pathway rather than direct VEGF stimulation.

That result is worth noting, but it comes with significant limits. It was presented as a conference abstract, not a full peer-reviewed study. It was conducted by researchers affiliated with the same lab that has produced most of the BPC-157 research globally. And in over twenty years, no independent group has replicated it.

More importantly, showing that a compound slows cell division in a lab dish does not tell you what it does inside a living body with an actual tumor. In vitro behavior and in vivo behavior are different enough that you cannot draw clean conclusions between them, and no one has tested BPC-157 in an animal model with an established tumor.

There is another mechanism worth naming. BPC-157 has been shown to activate something called FAK-paxillin signaling. FAK stands for focal adhesion kinase, and it is a protein involved in how cells attach to surfaces and migrate through tissue. That pathway is relevant because it is also implicated in cancer cell invasion, meaning how cancer cells move through tissue and spread beyond their original site. Whether BPC-157's activation of that pathway would matter in a real tumor environment is unknown. But the pathway being activated is not a neutral one.

A 2025 commentary published in Pharmaceuticals reviewed the current state of evidence and was direct about what is missing. There is no published in vivo data showing that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The conclusion from a 2025 narrative review in Current Reviews in Musculoskeletal Medicine was consistent with that: BPC-157 should be considered investigational until well-designed human trials are conducted.

So the actual answer to the question of whether BPC-157 causes cancer is that no evidence currently supports that conclusion. But the absence of evidence is doing a lot of work in that sentence, because no one has looked directly at the question in a living system.

The practical logic follows from the mechanism. If you have no history of cancer and no known elevated risk, the theoretical concern is real but unquantified, and you can make a reasonable judgment given that gap. If you have active cancer, a history of cancer, or a known precancerous condition, you are introducing a compound that upregulates a pathway tumors depend on, and there is no data to tell you whether that matters or how much.

The deeper issue here is not specific to BPC-157. It is that the VEGF system is not a repair switch you can flip on selectively. It is a pathway shared between healing tissue and growing tumors, and any compound that increases sensitivity across that whole system is not automatically safe or dangerous, it is simply not yet understood well enough to make that call.

That is what the data actually says.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness